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 Mesenchymal stem cells (MSCs) are adult 
stem cells with the capacity of self-renewal 
and trilineage differentiation into adi-
pocytes, chondroblasts, and osteoblasts. 
Th ey were fi rst isolated from the bone mar-
row of guinea pigs in 1970 by Friedenstein 
and colleagues on the basis of their proper-
ties of adherence to plastic and formation 
of fi broblast colonies. 1 MSCs have since 
been isolated from virtually every organ in 
mice, including fat, liver, spleen, pancreas, 
kidney, lung, muscle, and brain. In humans, 
MSCs have also been isolated from umbili-
cal cord tissue and cord blood, placenta, 
and joints. However, there is no unique cell-
surface marker distinguishing MSCs from 
other stem cells. Th e International Society 
for Cell Th erapy has suggested the follow-
ing minimal criteria to define human 
MSCs:  ‘ First, MSC must be plastic-adherent 
when maintained in standard culture con-
ditions. Second, MSC must express CD105, 
CD73 and CD90, and lack expression of 
CD45, CD34, CD14 or CD11b, CD79  or 
CD19 and HLA-DR surface molecules. 
Th ird, MSC must diff erentiate to osteo-
blasts, adipocytes and chondroblasts 
 in vitro .’ 2 Although these criteria have been 
adopted to identify MSCs isolated from 
other animal species, murine MSCs are 
known to express a diff erent set of markers. 
As cells are expanded in culture dishes, the 
surface molecules and their level of expres-
sion may change as well. 
 Bone marrow-derived MSCs (BM-
MSCs) constitute the major source of MSCs 
and are the best studied. Th e widely used 
method for isolation of BM-MSCs involves 
density gradient centrifugation to obtain 
nucleated cells, separation of non-adherent 
hematopoietic cells from plastic-adherent 
MSCs, and expansion of MSCs in culture. 
A similar method is used to isolate and 
expand MSCs from other organs. The 
resulting cells are usually heterogeneous 
with variable self-renewal and diff erentia-
tion capacities. Many of the cells represent 
mesenchymal stromal cells, thus raising the 
concern of  ‘ stemness ’ or true stem-cell 
property in the mixed population. Although 
MSCs isolated from diff erent sources share 
a considerable degree of overlap in their 
surface expression profi le, they are known 
to have variations in the pattern and level 
of expression at diff erent times in culture. 
For example, MSCs isolated from human 
adipose tissue are known to express CD34 
initially, but CD34 expression is downregu-
lated in culture. Presently, there are no uni-
form markers that identify MSCs isolated 
from all sources. 
 Roemeling-van Rhijn  et al. 3 (this issue) 
isolated MSCs from the adipose tissue of 
humans with end-stage renal disease 
(MSCs-RD) (mean glomerular fi ltration 
rate of 10.3  ml / min / 1.73  m 2 ) and control 
subjects (mean glomerular fi ltration rate of 
76.8  ml / min / 1.73  m 2 ) using a culture 
method ( Figure 1a ). Th e immunopheno-
type, adipogenic and osteogenic diff eren-
tiation, immunomodulation, and genetic 
stability of MSCs-RD were compared with 
those of control MSCs. Th e authors did not 
fi nd any diff erences in the above character-
istics. One interpretation of the results 
would be that the biological properties of 
adipose tissue – derived MSCs are not 
aff ected by renal failure. However, deriva-
tion of MSCs requires weeks of cultures in 
medium containing 15 % fetal bovine 
serum, so it is also possible that cells from 
either source may have undergone adapta-
tions in culture. To exclude this possibility, 
the authors performed fl ow cytometric 
analysis on freshly isolated CD34   +   and 
CD73   +   non-hematopoietic and non-
endothelial cells from adipose tissue. No 
difference in the expression of CD90, 
CD105, and CD166 was detected between 
MSCs isolated from controls and patients 
with renal disease, providing some reassur-
ance in surface molecular expression. It 
remains unknown whether freshly isolated 
MSCs from either renal patients or control 
subjects exhibit self-renewal and trilineage 
diff erentiation. Th e small number of cells 
before culture expansion limits further 
studies to answer this question. 
 Using mixed lymphocyte cultures, the 
authors showed that MSCs-RD inhibited 
the proliferation of activated peripheral 
blood mononuclear cells. To address 
whether this immunosuppressive ability 
was aff ected by uremia, the authors tested 
the eff ects of MSCs-RD in the presence of 
uremic serum and discovered that cell 
proliferation was inhibited similarly in 
the presence of uremic serum or control 
serum. Th is result could have clinical sig-
nifi cance if autologous MSCs are used to 
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induce or modulate immunosuppression 
in renal failure patients who need kidney 
transplantation. Animal and human stud-
ies have shown that the number and func-
tion of endothelial progenitor cells are 
reduced in renal failure. 4 Although stud-
ies presented by Roemeling-van Rhijn 
 et al. 3 did not examine whether uremic 
condition infl uenced the initial number 
of MSCs, the cells isolated from controls 
and patients with renal failure showed 
similar population-doubling time when 
both were maintained in culture condi-
tions up to 70 days. Taking a step further, 
the authors tested the population-
doubling time of MSCs-RD in cultures 
supplemented with 10 % control human 
serum or sera obtained from predialysis 
and dialysis patients. No diff erence in the 
proliferative capacity was detected, 
further supporting the conclusion that 
uremia does not affect the growth of 
MSCs in culture. Although the cells could 
be maintained in culture for months, the 
studies presented by Roemeling-van 
Rhijn  et al. 3 did not address whether 
they were true stem cells that could self-
renew and proliferate from a single cell 
colony. 
 Th e physiological function of BM-MSCs 
is to provide extracellular matrix, cyto-
kines, and growth factors that are needed 
for the normal development, maintenance, 
and diff erentiation of hematopoietic stem 
cells. MSCs are a rare population in the 
bone marrow, representing less than one 
in 30,000 nucleated cells. Under culture 
conditions, MSCs can be expanded within 
weeks to achieve the numbers needed for 
potential clinical application. In the past 
two decades, studies have explored the use 
of MSCs as immunomodulators, cell 
replacement agents, or delivery vehicles 
for therapeutic purposes ( Figure 1b ). 
Th ere are currently 225 registered clinical 
trials ( www.clinicaltrials.gov ) using MSCs 
to treat various conditions, including 
wound healing, bone defects, graft -vs.-
host disease, infl ammatory diseases, organ 
ischemic injury, and diabetes. To date, 
most trials are in the recruitment phase 
and have not had suffi  cient data to dem-
onstrate sustained eff ects. Animal studies 
have shown that administration of MSCs 
improves renal structure and function 
aft er acute kidney injury. Th e mechanism 
of renal protection is largely due to para-
crine eff ects that inhibit pro infl ammatory 
cytokines and stimulate anti-infl amma-
tory cytokines. 5 Although diff erentiation 
of MSCs into tubular epithelial cells has 
been reported, 6 most studies indicate that 
intravenously injected MSCs show mini-
mal homing to renal tubules and have lim-
ited survival in the kidney environment. 7 
A possible approach to enhance the thera-
peutic value of MSCs would be to increase 
homing to the kidney, for example, by 
overexpressing CD44. 8 Another interest-
ing area of research is the use of MSCs in 
conjunction with induction of immuno-
suppression in renal transplant recipients 
to modulate immunity. A pilot study of 
two patients who received intravenous 
injection of autologous bone marrow-
derived mesenchymal stromal cells 7 days 
aft er living-related kidney transplantation 
showed increased engraft ment of regula-
tory T cells in the peripheral blood and 
modulation of memory CD8 T-cell func-
tion. After one year of follow-up, both 
patients have stable renal function, and a 
protocol biopsy in one patient showed 
normal graft . 9 Long-term studies in larger 
populations are required to confi rm safety 
and effi  cacy. 
 Safety is a key issue in developing MSC-
based therapies. Intra-arterial injection of 
BM-MSCs in a rat model of anti-Th y1.1 
mesangioproliferative glomerulonephritis 
results in the appearance of adipocytes in 
20 % of glomeruli. Th e aff ected glomeruli 
show increased matrix deposition and scle-
rosis. 10 Th e undesired adipocyte diff eren-
tiation in the kidney offsets the initial 
benefi cial eff ects in preserving glomerular 
structure and reducing proteinuria. Like 
many other reports, this animal study raises 
important safety concerns that must be 
addressed before MSCs are used in clinical 
trials. Furthermore, injected MSCs have 
been shown to lead to tumor formation in 
multiple organs, which is thought to be due 
to chromosomal abnormalities that arise 
during expansion in culture. Roemeling-
van Rhijn  et al. 3 examined three samples of 
culture-expanded MSCs-RD using single-
nucleotide polymorphism-based whole-
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 Figure 1  |  Isolation, characterization, and potential therapeutic use of mesenchymal stem 
cells. ( a ) Adipose tissue – derived stem cells can be isolated by culture expansion of plastic-
adherent cells followed by cell characterization. Note that cells in culture are heterogeneous. 
They include mesenchymal stem cells, stromal cells, and fibroblasts. ( b ) Mesenchymal stem 
cells are characterized by their properties of self-renewal and differentiation into adipocytes, 
chondroblasts, and osteoblasts. The cells could potentially be used to treat diseases by providing 
immunomodulation, anti-inflammatory actions, and cell replacement as well as delivering 
therapeutic agents. 
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 genome analysis and did not detect any 
significant changes. Fluorescence  in situ 
hybridization of MSCs isolated from fi ve 
controls and three renal failure patients indi-
cated that more than 95 % of the cells had a 
normal karyotype. However, a small number 
of tetraploid cells were detected after 
ten population doublings, an amount of 
expansion that is oft en required to obtain 
a sufficient number of cells for clinical 
applications. 
 The studies by Roemeling-van Rhijn 
 et al. 3 demonstrated that the phenotype of 
adipose tissue – derived MSCs isolated from 
renal failure patients and control subjects 
is similar. While maintaining enthusiasm 
in using our own fat-tissue-derived MSCs 
for potential treatment of kidney disease, 
it is critical that we perform thorough test-
ing in animal models before conducting 
human studies and continue long-term 
monitoring for safety and effi  cacy. 
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 Interaction of receptor for 
advanced glycation end products 
with advanced oxidation protein 
products induces podocyte injury 
 Yasuhiko  Yamamoto 1 and  Hiroshi  Yamamoto 1 
 Chronic kidney disease (CKD) is characterized by progressive decline in 
renal function. Podocyte dropouts contribute to the pathogenesis of 
diabetic and nondiabetic CKD. Zhou and colleagues demonstrate that 
the association between advanced oxidation protein products (AOPPs) 
and receptor for advanced glycation end products (RAGE) elicited 
podocyte injuries, using cultured podocytes and mice injected with 
AOPPs. This study suggests that the blockade of RAGE is preventive 
and therapeutic against podocyte apoptosis caused by oxidative 
stress-related AOPPs in CKD. 
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 Chronic kidney disease (CKD) is a world-
wide health problem, with a rapidly 
increasing prevalence. Podocyte dysfunc-
tions, including podocyte loss and slit 
diaphragm disruptions, are closely linked 
to the pathogenesis of CKD. 1 Progressive 
kidney disease leading to end-stage renal 
disease is characterized by the progression 
of glomerulosclerosis and interstitial 
fi brosis. Th e common critical pathways 
could be involved in almost all forms of 
CKD. Th erefore, exploring the factors that 
can activate the pathways is important for 
the development of new strategies to pre-
vent and attenuate the development of 
CKD. The numerous factors that have 
been implicated in the initiation of the 
cascades include angiotensin II, growth 
factors, cytokines, oxidative and nitrosa-
tive stress, endoplasmic reticulum stress, 
mechanical stress, advanced glycation end 
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products (AGEs), and advanced oxidation 
protein products (AOPPs). AGEs are 
products of non-enzymatic glycation and 
oxidation of proteins and lipids, and AGE 
formation increases in situations with 
hyperglycemia and oxidative stress, such 
as diabetes mellitus. Recent clinical stud-
ies demonstrated that AOPPs are closely 
related to the initiation and progression of 
renal dysfunction in patients with a vari-
ety of diabetic and nondiabetic CKD. 2 In 
experimental animal studies, chronic 
administration of AOPPs accelerated 
renal fi brosis and deteriorated renal dys-
function. 2 AOPPs are thus considered 
causative factors in CKD. 
 Witko-Sarsat and colleagues 3 fi rst des-
ignated and described AOPPs in 1996. 
AOPPs abundantly contain dityrosines, 
which allow cross-linking through 
disulfi de bridges and carbonyl groups. 
AOPPs are formed mainly from chlorin-
ated oxidants, such as hypochloric acid 
and chloramines, partly through catalysis 
by myeloperoxidase. Neutrophils use the 
myeloperoxidase – H 2 O 2 – chloride system 
and form AOPPs and AGEs, such as  N    -
carboxymethyl-lysine and glycolaldehyde-
pyridine. 4 Characteristic chemical 
structures of heterogeneous AOPPs need 
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